(PHR) Phreesia - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US71944F1066
PHR: Scheduling, Registration, Payment, Referral, Insurance, Reminders
Phreesia Inc. stands as a prominent SaaS-based healthcare technology company, operating primarily in the United States and Canada. Specializing in patient engagement and revenue cycle management, they streamline clinical and financial workflows for healthcare providers, enhancing both patient experience and operational efficiency.
Their platform offers a suite of solutions, including appointment scheduling, reminders, and referral management, which facilitate seamless patient interactions. Additionally, they provide patient self-registration and revenue cycle tools that automate insurance verification and payment processing, offering flexible payment options to patients. Their Network Connect solution delivers targeted content to patients, further enriching their engagement.
Phreesias platform is accessible through various modalities: Phreesia Mobile for patient engagement on personal devices, Phreesia Dashboard for provider access via web, PhreesiaPads as self-service tablets, and Arrival Kiosks for on-site check-ins. This versatility ensures their solutions cater to diverse user needs, from patients to healthcare providers.
The company serves a broad clientele, including single and multi-specialty practices, health systems, and life sciences firms. Their scalable platform supports organizations of varying sizes, from small practices to large health systems, adapting to each clients unique requirements.
Financially, Phreesia boasts a market capitalization of approximately $1.7 billion, reflecting its significant presence in the healthcare technology sector. With a price-to-sales ratio of 4.31 and a forward P/E of 113.64, the company presents an intriguing valuation proposition for investors, indicating confidence in its growth potential.
Incorporated in 2005 and headquartered in Wilmington, Delaware, Phreesia continues to be a key player in the healthcare technology landscape. For more details, visit their website at https://www.phreesia.com.
Additional Sources for PHR Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PHR Stock Overview
Market Cap in USD | 1,479m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception | 2019-07-18 |
PHR Stock Ratings
Growth 5y | 3.47% |
Fundamental | 2.37% |
Dividend | 0.0% |
Rel. Strength Industry | 11.3 |
Analysts | 4.6/5 |
Fair Price Momentum | 21.93 USD |
Fair Price DCF | 3.08 USD |
PHR Dividends
No Dividends PaidPHR Growth Ratios
Growth Correlation 3m | 20.1% |
Growth Correlation 12m | 41.5% |
Growth Correlation 5y | -54.5% |
CAGR 5y | 7.05% |
CAGR/Max DD 5y | 0.08 |
Sharpe Ratio 12m | -0.08 |
Alpha | -0.52 |
Beta | 1.32 |
Volatility | 67.84% |
Current Volume | 804.6k |
Average Volume 20d | 440.5k |
As of March 15, 2025, the stock is trading at USD 25.45 with a total of 804,596 shares traded.
Over the past week, the price has changed by +7.52%, over one month by -14.71%, over three months by -0.74% and over the past year by +12.26%.
Neither. Based on ValueRay Fundamental Analyses, Phreesia is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 2.37 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PHR as of March 2025 is 21.93. This means that PHR is currently overvalued and has a potential downside of -13.83%.
Phreesia has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy PHR.
- Strong Buy: 9
- Buy: 6
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, PHR Phreesia will be worth about 24.9 in March 2026. The stock is currently trading at 25.45. This means that the stock has a potential downside of -2.32%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 32 | 25.7% |
Analysts Target Price | 31.2 | 22.6% |
ValueRay Target Price | 24.9 | -2.3% |